Mizuho Maintains Outperform on Biogen, Raises Price Target to $241

Benzinga Newsdesk www.benzinga.com Positive 89.6%

Neg 0% Neu 0% Pos 89.6%

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $221 to $241.